convalescent plasma treatment - versus control - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.50 [0.09, 2.71]< 10%1 study (1/-)78.8 %lownot evaluable highcrucial-
clinical deterioration 0.52 [0.29, 0.94]< 10%1 study (1/-)98.5 %lownot evaluable highimportant-
ICU admission 0.33 [0.07, 1.58]< 10%1 study (1/-)91.7 %lownot evaluable highnon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.